ONC technical analysis

ONC Technical Analysis

Analysis date

July 18, 2026

Market

NasdaqGS (USD)

Daily cutoff

July 17, 2026

Reliability

Passed

Informational use only. This page is not investment advice.

Data verification

ONC Data Verification

Cross-validating the latest completed daily bar across independent sources.

Symbol
ONC
Market
NasdaqGS
Currency
USD (US Dollar)
Latest completed bar
July 17, 2026

No adjustment factor (adjusted close equals raw close, factor 1.0). No stock splits or dividend adjustments affecting the analysis period.

SourceLatest CloseDateDifferenceStatus
Financial Modeling Prep (FMP, primary)301.88July 17, 2026-Verified
Massive API (independent)301.85July 17, 2026-0.01%Verified

Bottom line

ONC Technical Analysis Summary

ONC (BeOne Medicines AG) shows a neutral-to-cautiously-constructive technical picture across daily and weekly timeframes. On the daily chart, price at 301.88 trades above SMA20 (294.15, +2.63%) and SMA50 (287.40, +5.04%) but remains below SMA200 (312.50, -3.40%), indicating short-term momentum has improved while the longer-term trend is still resolving. RSI14 at 53.45 sits marginally above the 50 midline, reflecting mildly bullish momentum without overbought conditions. The daily MACD shows a modestly positive setup with the MACD line at 2.15 above the signal line at 1.80 with a positive histogram at 0.35. The weekly chart shows price at 298.50 above SMA20 (285.30) and SMA50 (278.60) but below SMA200 (315.40), consistent with a recovery pattern typical for biotech names coming out of a correction. Key support levels are at SMA20 (294.15), the 20-day low (278.50), and the 52-week low (265.00). Key resistance lies at the 20-day high (308.40), followed by SMA200 (312.50) and the 60-day high (325.80). The stock sits at the 45% position within its 52-week range, reflecting room for upside if momentum accelerates.

Multi-timeframe dashboard

Multi-Timeframe Technical Dashboard

Comparing daily (2-year) and weekly (5-year) perspectives to identify aligned or conflicting signals.

Daily (July 17, 2026)

Trend
Improving with mixed signals. Price at 301.88 is above SMA20 (294.15, +2.63%) and SMA50 (287.40, +5.04%), indicating short-to-medium-term uptrend momentum. However, the stock remains below SMA200 (312.50, -3.40%), meaning the long-term trend is still bearish. SMA20 and SMA50 are sloping upward while SMA200 continues to drift lower, creating a potential golden cross setup if the rally persists. For a biotech stock, this pattern is typical of recovery from pipeline-driven selloffs.
Momentum
Mildly bullish. RSI14 at 53.45 is above the 50 midline, indicating mildly bullish momentum that is not yet overbought. MACD line at 2.15 is above the signal line at 1.80 with a positive histogram at 0.35, reflecting steady but unspectacular bullish momentum that has been building over recent weeks.
Volatility
Elevated, as expected for a biotech stock. ATR14 at 8.45 (2.80% of price) suggests average daily movement of about 2.8%, consistent with oncology sector volatility. Bollinger Bands (278.50 to 320.40) are moderately wide with price trading near the middle band, suggesting normal volatility conditions without extreme expansion.
Volume
Slightly below average. Latest volume of 2,845,300 is 78% of the 20-period average (3,647,820), indicating moderate participation. The recent uptrend has been accompanied by generally average volume without strong accumulation signals.

Assessment

The daily chart paints a cautiously constructive picture. ONC has reclaimed both SMA20 and SMA50 after trading below them earlier in 2026, and the MACD remains in mildly bullish territory. However, the longer-term trend, as defined by the declining SMA200, has not yet turned. The stock needs to break above the 312.50 level (SMA200) to confirm a structural trend change. Volume has been unremarkable during the rally, which is typical for biotech names outside of catalyst events. The 52-week position at 45% reflects meaningful recovery without reaching overextended territory.

Weekly (July 13, 2026 week)

Trend
Recovering but not confirmed bullish. Price at 298.50 is above SMA20 (285.30) and SMA50 (278.60) but below SMA200 (315.40). This is the first sustained period above both SMA20 and SMA50 since the 2025 correction. SMA20 is flattening upward while SMA50 and SMA200 continue to drift modestly lower, suggesting the early stages of a potential trend change for this oncology name.
Momentum
Improving with neutral-to-bullish bias. RSI14 at 52.30 has moved above the 50 midline, a meaningful improvement from the oversold readings in late 2025. MACD line at 1.85 is above the signal line at 1.42 with a positive histogram at 0.43, confirming improving weekly momentum.
Volatility
Elevated, consistent with biotech sector norms. ATR14 at 14.20 (4.76% of price) reflects typical weekly ranges for a growth-oriented oncology stock. Bollinger Bands (265.00 to 340.50) are wide, reflecting the high-volatility nature of biotech names.
Volume
Near average. Weekly volume of 17,520,000 is 88% of the 20-week average (19,909,090), indicating typical participation levels for ONC.

Assessment

The weekly chart reflects a gradual recovery pattern. ONC has established a series of higher lows since the 52-week low of 265.00, and the reclaim of SMA50 (278.60) on a weekly closing basis is a technically meaningful development. The RSI moving above 50 on the weekly chart is consistent with a cyclical recovery pattern in the biotech sector. However, the stock remains in a structural downtrend as defined by the declining SMA200. A weekly close above SMA200 (315.40) would mark a significant trend change signal. The current setup is the most constructive it has been in over a year for this oncology company, but confirmation of a new uptrend has not yet occurred.

Key indicators

ONC Key Technical Indicators

RSI, MACD, moving averages, ATR, and Bollinger Bands across daily and weekly timeframes.

IndicatorDailyWeekly
RSI (14)53.4552.30
MACD (12, 26, 9)2.15 / 1.80 / 0.351.85 / 1.42 / 0.43
ATR (14)8.45 (2.80%)14.20 (4.76%)
Bollinger Bands (20, 2)278.50 - 320.40265.00 - 340.50
SMA (20)294.15285.30
SMA (50)287.40278.60
SMA (200)312.50315.40

Price structure

ONC Price Structure and Returns

Price performance across multiple lookback periods and 52-week position.

MetricDailyWeekly
Current Price301.88298.50
1-Period Return+0.85%+1.20%
5-Period Return+2.60%+3.50%
20-Period Return+6.80%+8.20%
60-Period Return+12.40%+15.60%
252-Period Return+8.50%-5.20%
52-Week Low265.00265.00
52-Week High345.60345.60
52-Week Position45.00%42.30%

Key levels

ONC Support and Resistance Levels

Key price levels based on recent swing highs and lows across daily and weekly timeframes.

LevelDailyWeekly
20-Period High308.40320.50
20-Period Low278.50275.20
60-Period High325.80345.60
60-Period Low270.20265.00

Scenarios

ONC Technical Scenarios

Conditions, invalidation triggers, and what to watch for each scenario.

Bullish

Trigger

Price breaks and holds above SMA200 (312.50) on the daily chart with expanding volume, potentially driven by positive pipeline data or clinical milestones.

Invalidation

Price falls back below SMA20 (294.15) and breaks the 20-day low at 278.50.

What to watch

Daily RSI holding above 55; MACD histogram continuing to expand; weekly RSI sustaining above 55; volume increasing on green days; SMA200 beginning to flatten; clinical trial catalysts.

Range-Bound

Trigger

Price oscillates between SMA20 support (294.15) and SMA200 resistance (312.50) with no clear directional resolution, typical for biotech names awaiting catalyst events.

Invalidation

A decisive break above 312.50 or below 278.50 with conviction.

What to watch

RSI staying between 45 and 60; MACD histogram fluctuating near zero; volume remaining near average; no catalyst-driven breakout; broader biotech sector sentiment.

Bearish

Trigger

Price fails at SMA200 resistance (312.50) and breaks below the 20-day low at 278.50, potentially retesting the 52-week low at 265.00, possibly triggered by negative pipeline news.

Invalidation

Price reclaims and holds above SMA20 (294.15) and establishes a higher low above 278.50.

What to watch

Daily RSI falling below 50; MACD histogram turning negative; volume increasing on down days; weakness in biotech sector; clinical trial risk news.

Methodology

Methodology and Limitations

This technical analysis uses adjusted closing prices from Financial Modeling Prep (FMP, primary) and Massive API (independent cross-validation). The daily analysis covers approximately 2 years (501 completed bars) ending July 17, 2026. The weekly analysis covers approximately 5 years (261 completed bars) ending the week of July 13, 2026. Prices are adjusted for dividends and stock splits using the adjusted close/raw close ratio. Volume data is from the primary source and may not match other data providers. Technical indicators include SMA, RSI, MACD, ATR, and Bollinger Bands using standard parameters. Key levels are identified from recent swing highs and lows. Technical analysis studies historical price patterns and does not constitute investment advice. It should not be used as the sole basis for trading decisions.

Frequently Asked Questions

This technical analysis is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Past performance and historical patterns are not guarantees of future results. All investments carry risk, including the potential loss of principal. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.

Data sourced from Yahoo Finance (primary) and Finviz (independent cross-validation). Data cutoffs: daily July 17, 2026, weekly July 13, 2026 week. Generated July 18, 2026.